This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
AbbVie's (ABBV) Rinvoq Meets Crohn's Disease Study Goals
by Zacks Equity Research
AbbVie's (ABBV) Rinvoq achieves statistical significance with its co-primary endpoints of clinical remission and endoscopic response in a late-stage study for Crohn's disease.
Epizyme (EPZM) Q1 Earnings Miss, Revenues Lag Estimates
by Zacks Equity Research
Epizyme (EPZM) posts a wider-than-expected loss for the first quarter. Revenues also miss estimates. EPZM has multiple pipeline readouts on track for this year.
Amicus (FOLD) Q1 Earnings Miss, Galafold Sales Top Estimates
by Zacks Equity Research
Amicus Therapeutics (FOLD) posts a wider-than-expected loss for the first quarter. FOLD's sole marketed drug Galafold's solid sales drive the top line.
bluebird (BLUE) Q1 Earnings and Sales Fall Short of Estimates
by Zacks Equity Research
bluebird's (BLUE) Q1 loss is worse than expected while sales lag estimates. It retains its dialogue with the FDA to resolve the clinical hold issue over its pipeline.
Bausch (BHC) Q1 Earnings and Revenues Miss, Stock Down
by Zacks Equity Research
Bausch (BHC) misses on earnings and sales in the first quarter due to incremental macro pressures and a challenging supply chain environment.
Intercept (ICPT) Q1 Earnings Top, Ocaliva Sales Miss Estimates
by Zacks Equity Research
Intercept (ICPT) posts a narrower-than-expected loss in the first quarter. Sales lag estimates.
Aerie (AERI) Q1 Loss Wider Than Expected, Revenues Rise Y/Y
by Zacks Equity Research
Aerie (AERI) misses on both earnings and revenues for the first quarter of 2022.
ChemoCentryx (CCXI) Q1 Earnings and Sales Miss Estimates
by Zacks Equity Research
ChemoCentryx (CCXI) posts a wider-than-anticipated Q1 loss and a revenue lag. However, product sales of CCXI's recently approved drug Tavneos grow five-fold from the previous quarter's levels.
Philips' (PHG) Collaboration Live Gets Nod for Remote Diagnosis
by Zacks Equity Research
Koninklijke Philips' (PHG) Collaboration Live integrated tele-ultrasound receives the expanded U.S. Food & Drug Administration 510(k) clearance for remote diagnostic use on additional mobile platforms.
Here's Why Abeona Therapeutics (ABEO) Looks Ripe for Bottom Fishing
by Zacks Equity Research
Abeona Therapeutics (ABEO) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Down 15.2% in 4 Weeks, Here's Why Abeona Therapeutics (ABEO) Looks Ripe for a Turnaround
by Zacks Equity Research
Abeona Therapeutics (ABEO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Moving Average Crossover Alert: Abeona Therapeutics (ABEO)
by Zacks Equity Research
Abeona Therapeutics (ABEO) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front
Abeona Therapeutics (ABEO) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Abeona Therapeutics (ABEO) delivered earnings and revenue surprises of -88.89% and -45.95%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Do Options Traders Know Something About Abeona (ABEO) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Abeona (ABEO) stock based on the movements in the options market lately.
Verastem (VSTM) Begins Phase II Combo Study for Ovarian Cancer
by Zacks Equity Research
Verastem (VSTM) initiates phase II registration-directed study of VS-6766 and defactinib in patients with recurrent low-grade serous ovarian cancer.
Is the Options Market Predicting a Spike in Abeona (ABEO) Stock?
by Zacks Equity Research
Investors need to pay close attention to Abeona (ABEO) stock based on the movements in the options market lately.
Biogen (BIIB) & Sage Therapeutics Partner for Depression Therapies
by Zacks Equity Research
Biogen (BIIB) and Sage Therapeutics (SAGE) collaborate to develop latter's zuranolone for depression indications and SAGE-324 for essential tremor.
HorizonTherapeutics (HZNP) Rises YTD on Approvals & Buyouts
by Zacks Equity Research
Horizon Therapeutics (HZNP) expects continued strong growth for Krystexxa and Tepezza in 2021. It is making efforts to expand the label for its marketed drugs.
Eiger (EIGR) Gets FDA Approval for Zokinvyin Rare Diseases
by Zacks Equity Research
Eiger (EIGR) gets FDA approval for Zokinvy for the treatment of Hutchinson-Gilford Progeria Syndrome and processing-deficient Progeroid Laminopathies.
Horizon (HZNP) and Halozyme Ink Deal for ENHANZE Technology
by Zacks Equity Research
Horizon (HZNP) inks deal to get an exclusive access to Halozyme's ENHANZE drug delivery technology for subcutaneous formulation of medicines targeting IGF-1R.
Amgen (AMGN) Ends Deal With Cytokinetics for Heart Candidate
by Zacks Equity Research
Amgen (AMGN) will terminate the collaboration with Cytokinetics and transition development and commercialization rights for omecamtiv mecarbil and AMG 594 to the latter.
Selecta's (SELB) Gene Therapy Gets Orphan Drug Tag From FDA
by Zacks Equity Research
The FDA bestows an orphan drug status on Selecta's (SELB) gene therapy candidate MMA-101 for the treatment of isolated methylmalonic acidemia. The candidate already has a Rare Pediatric Disease tag.
Apellis (APLS) Begins Dosing With Pegcetacoplan in ALS Study
by Zacks Equity Research
Apellis (APLS) and Sobi dose the first patient in the mid-stage MERIDIAN study, which is investigating pegcetacoplan to address adults with sporadic amyotrophic lateral sclerosis.
Palatin Technologies (PTN) Surges: Stock Moves 8% Higher
by Zacks Equity Research
Palatin Technologies (PTN) saw a big move last session, as its shares jumped 8% on the day, amid huge volumes.
Novo Nordisk's (NVO) Phase IIIb Study Meets Primary Endpoint
by Zacks Equity Research
Novo Nordisk's (NVO) semaglutide 2.0 mg demonstrates superior reduction in HbA1c versus once-weekly semaglutide 1.0 mg in people with type II diabetes.